reported that the serum IL-17A concentration in patients diagnosed with other types of gastric tumors (gastrointestinal stromal tumors, gastric neuroendocrine tumors, and primary gastric lymphomas) was significantly lower than that in healthy individuals and patients with gastric adenocarcinomas and provided evidence that tumor progression is not only caused by IL-17 secretion (35). This evidence concerns the gene IL17A and gastric adenocarcinoma.